



an Open Access Journal by MDPI

## Chemical Molecules Isolated from Natural Sources and Synthetic Drug Discovery for Liver and Kidney Disease

Guest Editors:

**Dr. Yanka D. Karamalakova**

Medical Faculty, Trakia  
University, Stara Zagora, Bulgaria

**Dr. Ekaterina Georgieva**

Medical Faculty, Trakia  
University, Stara Zagora, Bulgaria

Deadline for manuscript  
submissions:

**closed (31 August 2024)**

### Message from the Guest Editors

This Special Issue of *Biomedicines*, “Chemical molecules isolated from natural sources and Synthetic Drug Discovery for Liver and Kidney Disease”, aims to provide a comprehensive, multidisciplinary overview of the current knowledge in this field. We invite authors to submit original research articles and reviews that focus on the biochemical functions and therapeutic potential of the chemical molecules isolated from natural sources and synthetic drug discovery. Potential topics include, but are not limited to, the following:

- Drug discovery using chemical molecules isolated from natural sources;
- Synthetic drug discovery;
- Liver disease;
- Kidney disease;
- Metabolic/signaling pathways;
- Immuno-regulatory function;
- Reactive oxygen/nitrogen species;
- Metabolic processes;
- Biomarkers;
- Inflammation;
- Recent advances in liver and kidney therapies, based on protection with chemical molecules isolated from natural sources and synthetic drug discoveries.
- Recent advances in liver and kidney therapies, after symptomatic COVID-19, based on protection with the chemical molecules isolated from natural sources and synthetic drug discoveries.



[mdpi.com/si/200916](https://mdpi.com/si/200916)

Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI